SIRPA and atherosclerosis: Inhibitors of the CD47-SIRPα signaling axis, such as CD47 monoclonal antibodies and SHP1 inhibitors, can enhance macrophage efferocytosis in atherosclerosis, alleviating plaque inflammation and improving the condition of atherosclerosis [10,15].